Table 1.

The main trials about the different types of cell death.

Trial Identifier	Stage	Title/characteristics	Treatment	Comment	Cell death Type
NCT00326898	Phase 3	Clear Cell Renal Cell Carcinoma Stage I-III Renal Cell Cancer	sunitinib, sorafenib	No benefit to adjuvant sunitinib or sorafenib in ccRCC population	Ferroptosis
NCT00378703	Phase 2	Clear Cell Renal Cell Carcinoma Recurrent Renal Cell Carcinoma	sorafenib, temsirolimus	Not significantly improve median progression-free survival
NCT00126503	Phase 1 Phase 2	Chromophobe Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma	sorafenib tosylate	No benefit in ccRCC population
NCT02974738	Phase 1	Clear Cell Renal Cell Carcinom	Belzutifan	a high rate of disease control and durable responses
NCT02885649	Phase 1	Clear Cell Renal Cell Carcinoma Stage I Renal Cell Cancer	enzalutamide	Terminated	Apoptosis
NCT01391130	Phase 2	Metastatic Clear Cell Renal Cell Carcinoma	Sunitinib	Terminated	Neutrophils
NCT01158222	Phase 2	Clear Cell Renal Cell Carcinoma Stage IV Renal Cell Cancer	Sunitinib	No Results
NCT02917772	Phase 2	Clear-cell Metastatic Renal Cell Carcinoma	Nivolumab Ipilimumab	An approximately 10% improvement in ORR	Immunogenic cell death
NCT01408004	Phase 2	Clear Cell Renal Carcinoma	Everolimus Pazopanib	Did not result in prolonged progression-free-survival, fewer toxic effects, or improved quality of life	Immunogenic cell death
NCT03015740	Phase 1 Phase 2	Clear Cell Renal Cell Carcinoma Metastatic Kidney Carcinoma	Sitravatinib nivolumab	Demonstrated high clinical activity, manageable toxicity, and promising correlative immune effects	Ferroptosis Immunogenic cell death